Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.78 |
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | CA7 | P43166 | 3/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.68 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | TYR | P14679 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24464006 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL24464005 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL29753914 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL16131011 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL13973879 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL13963385 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL29380642 | 0.91 | CYP3A4 (0.83) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL572336 | 0.88 | CYP3A4 (1.00) | CBSCYP3A4RPS6KA3CYP2D6RPS6KA1 | |
| SCHEMBL30445487 | 0.86 | CA12 (0.81) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL31402522 | 0.86 | CA12 (0.86) | CBSCYP3A4CA12CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894400-B1 | COMPOSITIONS COMPRISING PLATANOSIDE AND ISOMERS THEREOF FOR USE IN THE TREATEMENT OF PANCREATIC, LIVER OR BRAIN CANCER | SHARE GAL RES AND DEVELOPMENT LTD (IL) | 2024-09-11 | — | — | EP | claimed |
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-05-31 | — | — | US | claimed |
| US-20220040213-A1 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-02-10 | — | — | US | claimed |
| EP-3894400-A1 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF | Share Gal Research And Development Ltd (IL) | 2021-10-20 | — | — | EP | claimed |
| WO-2020121297-A1 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2020-06-18 | — | — | WO | claimed |
| EP-3894400-C0 | COMPOSITIONS COMPRISING PLATANOSIDE AND ISOMERS THEREOF FOR USE IN THE TREATEMENT OF PANCREATIC, LIVER OR BRAIN CANCER | SHARE GAL RES AND DEVELOPMENT LTD (IL) | 2024-09-11 | — | — | EP | disclosed |
| EP-3894400-B1 | COMPOSITIONS COMPRISING PLATANOSIDE AND ISOMERS THEREOF FOR USE IN THE TREATEMENT OF PANCREATIC, LIVER OR BRAIN CANCER | SHARE GAL RES AND DEVELOPMENT LTD (IL) | 2024-09-11 | — | — | EP | disclosed |
| EP-3894400-B1 | COMPOSITIONS COMPRISING PLATANOSIDE AND ISOMERS THEREOF FOR USE IN THE TREATEMENT OF PANCREATIC, LIVER OR BRAIN CANCER | SHARE GAL RES AND DEVELOPMENT LTD (IL) | 2024-09-11 | — | — | EP | disclosed |
| EP-3894400-A4 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF | Share Gal Research And Development Ltd (IL) | 2022-07-27 | — | — | EP | disclosed |
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-05-31 | — | — | US | disclosed |
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-05-31 | — | — | US | disclosed |
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-05-31 | — | — | US | disclosed |
| US-8801924-B2 | Chromatography methods | IRONSTONE SEPARATIONS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8633166-B2 | Methicillin-resistant Staphylococcus aureus active metabolites | HAMANN, MARK T. | 2014-01-21 | — | — | US | disclosed |
| US-20130199999-A1 | Chromatography Methods | IRONSTONE SEPARATIONS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2590722-A1 | CHROMATOGRAPHY METHODS | Ironstone Separations, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012030432-A1 | CHROMATOGRAPHY METHODS | IRONSTONE SEPARATIONS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100273726-A1 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF | TRITON BIOPHARMA (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010107793-A1 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES | THE UNIVERSITY OF MISSISSIPPI (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100234311-A1 | Methicillin-Resistant Staphylococcus Aureus Active Metabolites | THE UNIVERSITY OF MISSISSIPPI (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040213-A1 | METHODS OF TREATING CANCER USING PLATANOSIDE AND ISOMERS THEREOF | EPHB3, EPHB1, FOLR1 | CBS 2108/4885CYP3A4 238/4885CA12 799/4885 |
| US-20100273726-A1 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF | MRPS18A, CD14, MRPL38 | CBS 4674/4885CYP3A4 3662/4885CA12 4493/4885 |
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | EPHB3, EPHB1, FOLR1 | CBS 2108/4885CYP3A4 238/4885CA12 799/4885 |
| US-20100234311-A1 | Methicillin-Resistant Staphylococcus Aureus Active Metabolites | HM13, FOS, MRPS23 | CBS 4757/4885CYP3A4 4387/4885CA12 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.